Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) Net Margin (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Net Margin for 3 consecutive years, with 28.77% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 49.0% to 28.77% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8.88% through Dec 2025, up 762.0% year-over-year, with the annual reading at 8.88% for FY2025, 759.0% up from the prior year.
  • Net Margin hit 28.77% in Q4 2025 for Immunocore Holdings, down from 0.19% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 10.83% in Q3 2024 to a low of 35.58% in Q1 2023.
  • Historically, Net Margin has averaged 16.04% across 3 years, with a median of 21.76% in 2023.
  • Biggest YoY gain for Net Margin was 4007bps in 2025; the steepest drop was -1102bps in 2025.
  • Year by year, Net Margin stood at 28.12% in 2023, then dropped by -1bps to 28.28% in 2024, then decreased by -2bps to 28.77% in 2025.
  • Business Quant data shows Net Margin for IMCR at 28.77% in Q4 2025, 0.19% in Q3 2025, and 10.51% in Q2 2025.